eNOS rs2070744 polymorphism might influence predisposition to hemorrhagic cerebral vascular diseases in East Asians: A meta‐analysis

Abstract

Introduction Endothelial nitric oxide synthase (eNOS) polymorphisms might influence predisposition to hemorrhagic cerebral vascular diseases, but the results of already published studies regarding relationship between eNOS polymorphisms and hemorrhagic cerebral vascular diseases were still controversial. Methods The authors performed this meta‐analysis to estimate relationship between eNOS polymorphisms and hemorrhagic cerebral vascular diseases in a larger pooled population by combing the results of already published related studies. The authors searched Pubmed, Embase, Web of Science, and CNKI for already published studies. Results Eighteen already published studies were pooled analyzed in this meta‐analysis. The pooled meta‐analyses results showed that eNOS rs2070744 polymorphism was significantly associated with predisposition to hemorrhagic cerebral vascular diseases in East Asians (dominant comparison: OR = 0.77, p = .01; overdominant comparison: OR = 1.24, p = .04; allele comparison: OR = 0.78, p = .006) Nevertheless, the pooled meta‐analyses did not reveal any positive results for eNOS rs1799983 and rs869109213 polymorphisms. Conclusions This meta‐analysis suggested that eNOS rs2070744 polymorphism, but not rs1799983 and rs869109213 polymorphisms, might influence predisposition to hemorrhagic cerebral vascular diseases in East Asians.

Identification of New Targets and the Virtual Screening of Lignans against Alzheimer’s Disease

“…The generalized expression of i NOS in the CNS is pathological and is often observed during neurological diseases, such as multiple sclerosis, stroke, and Parkinson's disease [ 85 ]. In patients with AD, studies have shown that the number of i NOS-positive neurons significantly increases in the brain and is associated with neuronal damage [ 86 ].…”

Is Hyperbaric Oxygen an Effective Treatment for the Prevention of Complications in SARS-CoV-2 Asymptomatic Patients?

“…16 There is a significant relation (odds ratio >1, range 1.24-2.74) between NOS gene polymorphisms and the comorbidities associated to 2020-2021 deaths due to coronavirus disease 2019 (COVID-19). 13,17,18 The virus acts following two distinct stages. During stage 1, after the incubation period, the SARS-CoV-2 virus activates mild symptoms and protective immune responses.…”

“…During stage 1, after the incubation period, the SARS-CoV-2 virus activates mild symptoms and protective immune responses. 18 During stage 2, a serious and damaging inflammatory response is activated. This affects mainly the lungs due to the triggering of a cytokines storm and the macrophage monocyte system.…”

“…This affects mainly the lungs due to the triggering of a cytokines storm and the macrophage monocyte system. 18 The successful elimination of the virus depends from the infected persons' human leukocyte antigen haplotype, their health condition, and the therapy promptness. 19 Our recommendation is to administer HBO2T (Figure 1) during stage 1 of SARS-CoV-2 infection.…”

“…The mean number of comorbidities was 3.6 (median 3, standard deviation 2.1), with 85.1% of the patients that died having 2 or more comorbidities 16 . There is a significant relation (odds ratio >1, range 1.24–2.74) between NOS gene polymorphisms and the comorbidities associated to 2020–2021 deaths due to coronavirus disease 2019 (COVID-19) 13,17,18 …”